US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beta Bionics, Inc.

22.44

-0.6099-2.65%

Volume:219.44K

Turnover:5.08M

Market Cap:975.47M

PE:-3.96

High:23.61

Open:23.28

Low:22.44

Close:23.05

52wk High:26.66

52wk Low:8.89

Shares:43.47M

Float Shares:23.74M

Volume Ratio:0.51

T/O Rate:0.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.6597

EPS(LYR):-8.6026

ROE:-81.35%

ROA:-21.78%

PB:3.11

PE(LYR):-2.61

Loading ...

Overview Company News Filings

BUZZ-Diabetes device makers fall after CMS proposes bidding program changes

BRIEF-Beta Bionics Announces Agreement With Abbott

Beta Bionics to Integrate iLet Bionic Pancreas with Abbott's Future Dual Sensor

Beta Bionics Initiated at Buy by Truist Securities

Truist Securities Initiates Beta Bionics at Buy With $26 Price Target

MT Newswires Live

Beta Bionics Coverage Assumed by Lake Street at Buy

Chief Commercial Officer Mark Hopman Reports Disposal of Common Shares of Beta Bionics Inc

CFO Stephen Feider Reports Disposal of Beta Bionics Inc. Common Shares

Beta Bionics Initiated at Outperform by Wolfe Research

Beta Bionics Q1 EPS $(0.93) Misses $(0.46) Estimate, Sales $17.64M Beat $16.15M Estimate

Press Release: Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

Beta Bionics Inc expected to post a loss of 48 cents a share - Earnings Preview

Beta Bionics to Host Investor Event on June 22, 2025

Stock Track | Beta Bionics (BBNX) Soars 5.21% Following Bank of America's Buy Rating Reiteration

Stock Track | Beta Bionics (BBNX) Soars 5.21% Following Bank of America's Buy Rating Reiteration

Press Release: Beta Bionics Announces Board Appointment of Gerard Michel

Beta Bionics Reports Q4 Loss as Sales Rise; Sets 2025 Revenue Guidance

MT Newswires Live

Beta Bionics Q4 2024 GAAP EPS $(2.72) Beats $(2.91) Estimate, Sales $20.400M Beat $20.187M Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BBNX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBNX\",,,,,undefined,":{"symbol":"BBNX","market":"US","secType":"STK","nameCN":"Beta Bionics, Inc.","latestPrice":22.4401,"timestamp":1758299524863,"preClose":23.05,"halted":0,"volume":219438,"delay":0,"floatShares":23735244,"shares":43470125,"eps":-5.659705,"marketStatus":"Trading","change":-0.6099,"latestTime":"09-19 12:32:15 EDT","open":23.28,"high":23.6116,"low":22.44,"amount":5083953.628032,"amplitude":0.050829,"askPrice":22.65,"askSize":5,"bidPrice":22.53,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-5.659705,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1758312000000},"marketStatusCode":2,"adr":0,"listingDate":1738213200000,"exchange":"NASDAQ","adjPreClose":23.05,"postHourTrading":{"tag":"盘后","latestPrice":23.05,"preClose":23.05,"latestTime":"17:32 EDT","volume":1805,"amount":41605.42,"timestamp":1758231153601},"volumeRatio":0.509041},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBNX\",,,,,undefined,":{"symbol":"BBNX","floatShares":23735244,"roa":"-21.78%","roe":"-81.35%","lyrEps":-8.602584,"volumeRatio":0.509041,"shares":43470125,"dividePrice":0,"high":23.6116,"amplitude":0.050829,"preClose":23.05,"low":22.44,"week52Low":8.89,"pbRate":"3.11","psRate":"13.97","week52High":26.66,"institutionHeld":0,"latestPrice":22.4401,"eps":-5.659705,"divideRate":0,"volume":219438,"delay":0,"ttmEps":-5.659705,"open":23.28,"prevYearClose":17,"prevWeekClose":26.41,"prevMonthClose":18.84,"prevQuarterClose":14.56,"fiveDayClose":26.41,"twentyDayClose":16.89,"sixtyDayClose":14.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBNX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"BBNX","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753761600000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2025-05-06","symbol":"BBNX","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"post","actualEps":-0.52},{"market":"US","date":"2025-03-25","symbol":"BBNX","fiscalQuarterEnding":"2024/12","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742875200000,"reportTimeType":"post","actualEps":-1.82}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBNX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBNX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.3333,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":9,"updateTime":1750132800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBNX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBNX","date":"2025-09-17","current":-14.26686,"percent":0.169811,"low":-18.401318,"twenty":-13.013188,"median":-10.038359,"eighty":-8.656151,"high":-3.90273,"avg":-11.000772,"sd":3.004774,"marketCap":1012419211},"quantilePoints":[{"date":"2025-01-31","current":-18.262207,"twenty":-16.058067,"median":-12.751858,"eighty":-7.442381,"marketCap":1013479428},{"date":"2025-02-07","current":-18.125788,"twenty":-18.207639,"median":-17.701026,"eighty":-14.679009,"marketCap":1005908733},{"date":"2025-02-14","current":-16.797439,"twenty":-18.139689,"median":-17.569735,"eighty":-16.871579,"marketCap":932190666},{"date":"2025-02-21","current":-16.117818,"twenty":-18.053192,"median":-17.39983,"eighty":-16.806707,"marketCap":894474446},{"date":"2025-02-28","current":-15.376414,"twenty":-17.738096,"median":-16.901699,"eighty":-15.527784,"marketCap":853329479},{"date":"2025-03-07","current":-13.754592,"twenty":-17.625341,"median":-16.797439,"eighty":-14.919215,"marketCap":763324863},{"date":"2025-03-14","current":-10.843036,"twenty":-17.540388,"median":-16.156433,"eighty":-12.952405,"marketCap":601745147},{"date":"2025-03-21","current":-12.117325,"twenty":-17.418365,"median":-15.88613,"eighty":-12.19996,"marketCap":672463060},{"date":"2025-03-28","current":-10.030495,"twenty":-17.316422,"median":-15.090664,"eighty":-11.612243,"marketCap":549229802},{"date":"2025-04-04","current":-8.526317,"twenty":-16.978156,"median":-13.955389,"eighty":-11.224551,"marketCap":466867006},{"date":"2025-04-11","current":-8.462983,"twenty":-16.936452,"median":-12.789848,"eighty":-9.75816,"marketCap":463399099},{"date":"2025-04-17","current":-8.660901,"twenty":-16.843777,"median":-12.343221,"eighty":-9.270489,"marketCap":474236309},{"date":"2025-04-25","current":-8.755902,"twenty":-16.843777,"median":-12.117325,"eighty":-8.660901,"marketCap":479438170},{"date":"2025-05-02","current":-8.819236,"twenty":-16.797439,"median":-11.630778,"eighty":-8.660901,"marketCap":482906077},{"date":"2025-05-09","current":-9.109566,"twenty":-16.202771,"median":-11.468596,"eighty":-8.660901,"marketCap":646442149},{"date":"2025-05-16","current":-8.41306,"twenty":-16.195048,"median":-11.020664,"eighty":-8.526317,"marketCap":597015989},{"date":"2025-05-23","current":-9.476148,"twenty":-16.117818,"median":-10.030495,"eighty":-8.550067,"marketCap":672455918},{"date":"2025-05-30","current":-9.384503,"twenty":-15.951002,"median":-9.677769,"eighty":-8.619734,"marketCap":665952476},{"date":"2025-06-06","current":-11.944468,"twenty":-15.890764,"median":-10.161718,"eighty":-8.656151,"marketCap":847615293},{"date":"2025-06-13","current":-11.90781,"twenty":-15.527784,"median":-10.843036,"eighty":-8.663027,"marketCap":845013916},{"date":"2025-06-20","current":-10.863051,"twenty":-15.401128,"median":-10.973025,"eighty":-8.671464,"marketCap":770874676},{"date":"2025-06-27","current":-9.158444,"twenty":-15.033515,"median":-10.853044,"eighty":-8.690985,"marketCap":649910652},{"date":"2025-07-03","current":-8.260318,"twenty":-14.588672,"median":-10.413035,"eighty":-8.668829,"marketCap":586176919},{"date":"2025-07-11","current":-8.284756,"twenty":-14.14074,"median":-9.690076,"eighty":-8.535817,"marketCap":587911170},{"date":"2025-07-18","current":-8.043423,"twenty":-13.87507,"median":-9.628891,"eighty":-8.433029,"marketCap":570785439},{"date":"2025-07-25","current":-8.816301,"twenty":-13.38389,"median":-9.506697,"eighty":-8.433029,"marketCap":625631134},{"date":"2025-08-01","current":-10.285126,"twenty":-12.797445,"median":-9.491423,"eighty":-8.48456,"marketCap":729863398},{"date":"2025-08-08","current":-9.243749,"twenty":-12.637058,"median":-9.506697,"eighty":-8.519369,"marketCap":655964186},{"date":"2025-08-15","current":-10.23612,"twenty":-12.367549,"median":-9.430326,"eighty":-8.524348,"marketCap":726385788},{"date":"2025-08-22","current":-10.346383,"twenty":-12.210773,"median":-9.506697,"eighty":-8.53478,"marketCap":734210411},{"date":"2025-08-29","current":-11.461269,"twenty":-12.163662,"median":-9.628891,"eighty":-8.548511,"marketCap":813326038},{"date":"2025-09-05","current":-12.312748,"twenty":-12.179108,"median":-9.681286,"eighty":-8.567484,"marketCap":873749512},{"date":"2025-09-12","current":-15.522638,"twenty":-12.446687,"median":-9.727683,"eighty":-8.641901,"marketCap":1101532967},{"date":"2025-09-17","current":-14.26686,"twenty":-13.013188,"median":-10.038359,"eighty":-8.656151,"marketCap":1012419211}],"updateTime":1758261444976},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBNX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548600647","title":"BUZZ-Diabetes device makers fall after CMS proposes bidding program changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2548600647","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548600647?lang=en_us&edition=fundamental","pubTime":"2025-07-01 20:02","pubTimestamp":1751371368,"startTime":"0","endTime":"0","summary":"BUZZ-Diabetes device makers fall after CMS proposes bidding program changes** Shares of diabetes device makers DexCom DXCM.O and Tandem Diabetes Care TNDM.O fall nearly 4% each premarket** DXCM down 3.8% at $84, while TNDM down 3.9% at $17.92** The Centers for Medicare and Medicaid Services late on Monday proposed changes to the competitive bidding program aimed at lowering diabetes patients' copay for insulin pumps, continuous glucose monitors and other devices     ** J.P.Morgan says changes would affect Abbott ABT.N and DXCM, who manufacture CGMs, as well as insulin pump makers TNDM and Beta Bionics BBNX.O ** Brokerage says the Office of Inspector General is reviewing CGMs with the goal of checking distributor margins, and not target manufacturer prices    ** J.P.Morgan believes current CGM distributor margins of about 70% are appropriate and don't expect any near-term pricing impact on ABT or DXCM from the OIG review** \"However, we'd expect over time for CGM pricing to continue to m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL4N3SY0QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU2089984988.USD","LU0170899867.USD","BK4082","IE00B4R5TH58.HKD","LU2237957902.USD","IE00BFTCPJ56.SGD","TNDM","SG9999002232.USD","BK4585","LU0266013472.USD","IE00BJT1NW94.SGD","LU0354030438.USD","SG9999002224.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU2211815571.USD","ABT","LU0234572021.USD","LU2125909593.SGD","BK4534","LU0122379950.USD","IE00BMPRXN33.USD","LU1989763690.USD","LU2237957811.SGD","SGXZ23171101.USD","BBNX","DXCM","BK4533","LU1914381329.SGD","LU1721429402.USD","LU1061106388.HKD","IE0009355771.USD","LU1057294990.SGD","BK4548","IE0002141913.USD","LU1721429741.USD","LU2133065610.SGD","BK4566","LU0354030511.USD","LU2125909247.SGD","LU1691799644.USD","BK4581","LU0868494617.USD","LU1989763427.SGD","LU1923622614.USD","BK4504","BK4551","IE00BMPRXR70.SGD"],"gpt_icon":0},{"id":"2544519864","title":"BRIEF-Beta Bionics Announces Agreement With Abbott","url":"https://stock-news.laohu8.com/highlight/detail?id=2544519864","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544519864?lang=en_us&edition=fundamental","pubTime":"2025-06-19 23:58","pubTimestamp":1750348729,"startTime":"0","endTime":"0","summary":"BRIEF-Beta Bionics Announces Agreement With AbbottJune 19 (Reuters) - Beta Bionics Inc BBNX.O:BETA BIONICS ANNOUNCES AGREEMENT WITH ABBOTT TO INTEGRATE THE ILET BIONIC PANCREAS WITH ABBOTT’S FUTURE DU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nTUA7LJWVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BBNX"],"gpt_icon":0},{"id":"2544343166","title":"Beta Bionics to Integrate iLet Bionic Pancreas with Abbott's Future Dual Sensor","url":"https://stock-news.laohu8.com/highlight/detail?id=2544343166","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544343166?lang=en_us&edition=fundamental","pubTime":"2025-06-19 19:00","pubTimestamp":1750330823,"startTime":"0","endTime":"0","summary":"Beta Bionics, Inc., a leader in advanced diabetes management solutions, has announced a new agreement with Abbott to integrate its iLet Bionic Pancreas with Abbott's upcoming dual glucose-ketone sensor in the United States. The iLet system, renowned for its fully automated insulin dosing capabilities, aims to enhance diabetes care by eliminating the need for carb counting and manual insulin corrections. This partnership builds on the existing collaboration between Beta Bionics and Abbott, currently supporting the FreeStyle Libre 3 Plus sensor, and underscores their commitment to advancing real-time decision-making support for people with diabetes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL2lQrK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4082","BBNX","LU2210150020.SGD","LU2210149790.SGD","BK4112","BK4585","BK4588","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2544604884","title":"Beta Bionics Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2544604884","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544604884?lang=en_us&edition=fundamental","pubTime":"2025-06-17 00:16","pubTimestamp":1750090560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2025 12:16 ET (16:16 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BBNX"],"gpt_icon":0},{"id":"2543675728","title":"Truist Securities Initiates Beta Bionics at Buy With $26 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2543675728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543675728?lang=en_us&edition=fundamental","pubTime":"2025-06-16 18:17","pubTimestamp":1750069041,"startTime":"0","endTime":"0","summary":"Beta Bionics (BBNX) has an average rating of overweight and mean price target of $23.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBNX"],"gpt_icon":0},{"id":"2542511412","title":"Beta Bionics Coverage Assumed by Lake Street at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2542511412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542511412?lang=en_us&edition=fundamental","pubTime":"2025-06-12 20:32","pubTimestamp":1749731520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2025 08:32 ET (12:32 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX","BK4082"],"gpt_icon":0},{"id":"2541975880","title":"Chief Commercial Officer Mark Hopman Reports Disposal of Common Shares of Beta Bionics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541975880","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541975880?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:30","pubTimestamp":1749079857,"startTime":"0","endTime":"0","summary":"Mark Hopman, the Chief Commercial Officer of Beta Bionics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9dwHP0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BBNX"],"gpt_icon":0},{"id":"2541304097","title":"CFO Stephen Feider Reports Disposal of Beta Bionics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541304097","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541304097?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:30","pubTimestamp":1749079841,"startTime":"0","endTime":"0","summary":"Stephen Feider, the Chief Financial Officer of Beta Bionics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL707Wn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Stephen Feider Reports Disposal of Beta Bionics Inc. Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX","BK4082"],"gpt_icon":0},{"id":"2539276494","title":"Beta Bionics Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2539276494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539276494?lang=en_us&edition=fundamental","pubTime":"2025-05-30 23:45","pubTimestamp":1748619900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 11:45 ET (15:45 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0},{"id":"2533662804","title":"Beta Bionics Q1 EPS $(0.93) Misses $(0.46) Estimate, Sales $17.64M Beat $16.15M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533662804","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533662804?lang=en_us&edition=fundamental","pubTime":"2025-05-07 04:21","pubTimestamp":1746562868,"startTime":"0","endTime":"0","summary":"Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.46) by 102.17 percent. This is a 55.07 percent increase over losses of $(2.07) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45236249/beta-bionics-q1-eps-0-93-misses-0-46-estimate-sales-17-64m-beat-16-15m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0},{"id":"2533661620","title":"Press Release: Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533661620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533661620?lang=en_us&edition=fundamental","pubTime":"2025-05-07 04:02","pubTimestamp":1746561720,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., May 06, 2025  -- Beta Bionics, Inc. , a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025.-- Net sales of $17.6 million, up 36% compared to $12.9 million in the first. -- Durable Medical Equipment  channel net sales of $13.8 million,up 14% compared to $12.1 million in the first quarter of 2024.-- Pharmacy Benefit Plan  channel net sales of $3.8 million, up. 360% compared to $0.8 million in the first quarter of 2024.-- Gross margin of 50.9%, down 482 basis points compared to 55.7% in the. -- Installed customer base (calculated as all new patient starts over a. rolling four-year period) of 19,151 users, up 291% compared to 4,901 in. -- 3,853 new patient starts, up 48% compared to 2,597 new patient starts in. million or negative 96% of sales in the first quarter of 2024.((1) () See \"Non-GAAP Financial M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PBP","BBNX"],"gpt_icon":0},{"id":"2532803389","title":"Beta Bionics Inc  expected to post a loss of 48 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2532803389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532803389?lang=en_us&edition=fundamental","pubTime":"2025-05-03 06:48","pubTimestamp":1746226084,"startTime":"0","endTime":"0","summary":"Beta Bionics Inc  expected to post a loss of48cents a share - Earnings Preview Beta Bionics Inc BBNX.OQ BBNX.O is expected to report resultson May 6 for the period ending March 31 2025The Irvine Calif","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL8N3RA3GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0},{"id":"2526508143","title":"Beta Bionics to Host Investor Event on June 22, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526508143","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526508143?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:30","pubTimestamp":1744198200,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., April  09, 2025  (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058311/0/en/Beta-Bionics-to-Host-Investor-Event-on-June-22-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4181","BK4588","BK4082","BBNX","BK4218","HST"],"gpt_icon":0},{"id":"1143484942","title":"Stock Track | Beta Bionics (BBNX) Soars 5.21% Following Bank of America's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1143484942","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143484942?lang=en_us&edition=fundamental","pubTime":"2025-04-01 00:28","pubTimestamp":1743438507,"startTime":"0","endTime":"0","summary":"Shares of Beta Bionics, Inc.  are soaring 5.21% in intraday trading on Monday, following a positive analyst report from Bank of America Securities. Analyst Travis Steed reiterated a Buy rating on the stock, signaling continued confidence in the company's growth prospects.Beta Bionics, known for its innovative medical technologies, has been gaining attention from investors and analysts alike. The company's strategic expansion plans and potential market opportunities appear to be driving the optim","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BBNX"],"gpt_icon":0},{"id":"1100546963","title":"Stock Track | Beta Bionics (BBNX) Soars 5.21% Following Bank of America's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1100546963","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100546963?lang=en_us&edition=fundamental","pubTime":"2025-04-01 00:28","pubTimestamp":1743438507,"startTime":"0","endTime":"0","summary":"Shares of Beta Bionics, Inc.  are soaring 5.21% in intraday trading on Monday, following a bullish analyst report from Bank of America Securities. The stock's significant uptick comes after analyst Travis Steed reiterated a Buy rating on BBNX, highlighting the company as an undervalued growth opportunity.In the report released early Monday, Steed emphasized Beta Bionics' strategic expansion plans as a key factor in his positive outlook. While specific details of the report were not immediately a","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Beta Bionics (BBNX) Soars 5.21% Following Bank of America's Buy Rating Reiteration","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BBNX"],"gpt_icon":0},{"id":"2522534031","title":"Press Release: Beta Bionics Announces Board Appointment of Gerard Michel","url":"https://stock-news.laohu8.com/highlight/detail?id=2522534031","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522534031?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:45","pubTimestamp":1743108300,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., March 27, 2025  -- Beta Bionics, Inc. , a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems , a commercial-stage interventional oncology company.Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across numerous functional areas. Prior to joining Delcath Systems as Chief Executive Officer in 2020, Mr. Michel served as Chief Financial Officer at Vericel Corporation, a biopharmaceutical company. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development at Biodel, Inc. from November 2007 to May 2014, and Chief Financial Officer and Vice President of Corporate Development at NPS Pharmaceuticals Inc. from August 2002 to November 2007. Previously, Mr. Michel was a Principal at Booz All","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX","BK4082"],"gpt_icon":0},{"id":"2522915833","title":"Beta Bionics Reports Q4 Loss as Sales Rise; Sets 2025 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2522915833","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522915833?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:50","pubTimestamp":1742935835,"startTime":"0","endTime":"0","summary":"Beta Bionics  reported a Q4 net loss late Tuesday of $2.72 per diluted share.The company did not provide a year-ago per-share figure.Analysts polled by Factset expected a loss of $0.90.Net sales for the quarter ended Dec. 31 were $20.4 million, up from $8.4 million a year earlier.Analysts surveyed by Factset expected $20.2 million.The company set full-year 2025 revenue guidance between $80 million and $85 million.Analysts polled by Factset expect $85.1 million.Beta Bionics completed its initial public offering on Jan. 30, listing on the Nasdaq Global Market.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBNX"],"gpt_icon":0},{"id":"2522887701","title":"Beta Bionics Q4 2024 GAAP EPS $(2.72) Beats $(2.91) Estimate, Sales $20.400M Beat $20.187M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887701","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887701?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:09","pubTimestamp":1742933340,"startTime":"0","endTime":"0","summary":"Beta Bionics Q4 2024 GAAP EPS $(2.72) Beats $(2.91) Estimate, Sales $20.400M Beat $20.187M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44481372/beta-bionics-q4-2024-gaap-eps-2-72-beats-2-91-estimate-sales-20-400m-beat-20-187m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBNX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}